CDK8-IN-14 is a small molecule inhibitor specifically targeting cyclin-dependent kinase 8 (CDK8), which plays a crucial role in regulating transcription and cell cycle progression. This compound is part of a broader class of CDK inhibitors that have garnered interest for their potential therapeutic applications in cancer treatment, particularly in tumors with aberrant CDK8 activity. CDK8-IN-14 is characterized by its ability to selectively inhibit CDK8 without significantly affecting other CDK family members, which may reduce off-target effects and enhance its therapeutic profile. The compound's structure typically includes specific functional groups that facilitate binding to the ATP-binding site of CDK8, thereby blocking its kinase activity. In preclinical studies, CDK8-IN-14 has shown promise in reducing cell proliferation and inducing apoptosis in cancer cell lines, making it a candidate for further investigation in clinical settings. As research progresses, understanding its pharmacokinetics, bioavailability, and potential side effects will be essential for evaluating its efficacy and safety in human subjects.

CDK8-IN-14

2924193-12-2: CDK8-IN-14 is a small molecule inhibitor specifically targeting cyclin-dependent kinase 8 (CDK8), which plays a crucial role in regulating transcription and cell cycle progression. This compound is part of a broader class of CDK inhibitors that have garnered interest for their potential therapeutic applications in cancer treatment, particularly in tumors with aberrant CDK8 activity. CDK8-IN-14 is characterized by its ability to selectively inhibit CDK8 without significantly affecting other CDK family members, which may reduce off-target effects and enhance its therapeutic profile. The compound's structure typically includes specific functional groups that facilitate binding to the ATP-binding site of CDK8, thereby blocking its kinase activity. In preclinical studies, CDK8-IN-14 has shown promise in reducing cell proliferation and inducing apoptosis in cancer cell lines, making it a candidate for further investigation in clinical settings. As research progresses, understanding its pharmacokinetics, bioavailability, and potential side effects will be essential for evaluating its efficacy and safety in human subjects.

<p>CDK8-IN-14 (compound 12) effectively inhibits CDK8, demonstrating an IC50 of 39.2 nM, and exhibits potent anti-AML cell proliferation effects, with a GC50 value of 0.02±0.01μM in MOLM-13 cells and 0.03±0.01μM in MV4-11 cells [1].</p>

CAS 2924193-12-2

CDK8-IN-14

CDK8-IN-14

Ref: TM-T86031